Delaying treatment of ocular hypertension: The ocular hypertension treatment study

Archives of Ophthalmology

Volumn 128, Issue 3, 2010, Pages 276-287

  Kass, Michael A ^a   Gordon, Mae O ^a   Gao, Feng ^a   Heuer, Dale K ^b   Higginbotham, Eve J ^c   Johnson, Chris A ^d   Keltner, John K ^e   Philip Miller, J ^a   Parrish, Richard K ^f   Wilson, M Roy ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARGON LASER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; QUESTIONNAIRE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; TRABECULOPLASTY; TRABECULOTOMY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL FIELD;

ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; QUESTIONNAIRES; RISK FACTORS; SCOTOMA; SICKNESS IMPACT PROFILE; TIME FACTORS; VISUAL FIELDS;

EID: 77749330689     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.20     Document Type: Article

References (28)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol. 1996; 80(5):389-393.
2. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 1991;325(20):1412-1417.
3. US Department of Health, Education, and Welfare. Statistics on blindness in the model reporting area 1969-1970. Washington, DC: US Government Printing Office; 1973.
4. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38(1):83-91.
5. Hyman L, Wu SY, Connell AM, et al. Prevalence and causes of visual impairment in the Barbados Eye Study. Ophthalmology. 2001;108(10):1751- 1756.
6. Mason RP, Kosoko O, Wilson MR, et al. National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies, part I: prevalence findings. Ophthalmology. 1989;96(9):1363-1368.
7. Wallace J, Lovell HG. Glaucoma and intraocular pressure in Jamaica. Am J Ophthalmol. 1969;67(1):93-100.
8. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma: The Baltimore Eye Survey. JAMA. 1991;266(3):369-374.
9. Leske MC, Connell AM, Wu SY, et al; The Barbados Eye Studies Group. Incidence of open-angle glaucoma: the Barbados Eye Studies. Arch Ophthalmol. 2001;119(1):89-95.
10. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119(12):1819-1826.
11. Varma R, Ying-Lai M, Francis BA, et al; Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111(8):1439-1448.
12. Rossetti L, Marchetti I, Orzalesi N, Scorpiglione N, Torri V, Liberati A. Randomized clinical trials on medical treatment of glaucoma: are they appropriate to guide clinical practice? Arch Ophthalmol. 1993;111(1):96-103.
13. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713, discussion 829-830.
14. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO; Ocular Hypertension Treatment Study Group (OHTS). Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2006;141(6):997-1008.
15. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma, II: the site of injury and susceptibility to damage. Arch Ophthalmol. 1981;99(4):635-649.
16. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999;117(5):573-583.
17. Lee BL, Gutierrez P, Gordon M, et al. The Glaucoma Symptom Scale: a brief index of glaucoma-specific symptoms. Arch Ophthalmol. 1998;116(7):861-866.
18. Johnson CA, Keltner JL, Cello KE, et al; Ocular Hypertension Study Group. Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology. 2002;109(3):432-437.
19. Feuer WJ, Parrish RK II, Schiffman JC, et al. The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. Am J Ophthalmol. 2002;133(1):19-28.
20. Breslow NE, Day NE. Statistical methods in cancer research: volume II - the design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1-406.
21. Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat Med. 2007;26(24):4505-4519.
22. Kiuchi AS, Hartigan JA, Holford TR, Rubinstein P, Stevens CE. Change points in the series of T4 counts prior to AIDS. Biometrics. 1995;51(1):236-248.
23. Gordon MO, Torri V, Miglior S, et al; Ocular Hypertension Treatment Study Group; European Glaucoma Prevention Study Group. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology. 2007;114(1):10-19.
24. Hertzog LH, Albrecht KG, LaBree L, Lee PP. Glaucoma care and conformance with preferred practice patterns: examination of the private, community-based ophthalmologist. Ophthalmology. 1996;103(7):1009-1013.
25. Leske MC, Wu SY, Nemesure B, Hennis A; Barbados Eye Studies Group. Risk factors for incident nuclear opacities. Ophthalmology. 2002;109(7):1303-1308.
26. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.
27. Glynn RJ, Seddon JM, Krug JH Jr, Sahagian CR, Chiavelli ME, Campion EW. Falls in elderly patients with glaucoma. Arch Ophthalmol. 1991;109(2):205-210.
28. Wu SY, Nemesure B, Hennis A, Schachat AP, Hyman L, Leske MC; Barbados Eye Studies Group. Open-angle glaucoma and mortality: The Barbados Eye Studies. Arch Ophthalmol. 2008;126(3):365-370.